Obesity and Age-Related Changes in Markers of Oxidative Stress and Inflammation Across Four Generations

Obesity

Volumn 24, Issue 6, 2016, Pages 1389-1396

  Hulsegge, Gerben ^a,b   Herber Gast, Gerrie Cor M ^a,c   Spijkerman, Annemieke M W ^a   Susan, H ^e   Picavet, J ^a   van der Schouw, Yvonne T ^b   Bakker, Stephan J L ^d   Gansevoort, Ron T ^d   Dollé, Martijn E T ^a   Smit, Henriette A ^b   Monique Verschuren, W M ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; URIC ACID;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL EXAMINATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; WEIGHT CONTROL;

EID: 84990214096     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21515     Document Type: Article

References (40)

1. Hulsegge G, Picavet HS, Blokstra A, et al. Today's adult generations are less healthy than their predecessors: generation shifts in metabolic risk factors: the Doetinchem Cohort Study. Eur J Prev Cardiol 2014;21:1134–1144.
2. Ulmer H, Kelleher CC, Fitz-Simon N, Diem G, Concin H. Secular trends in cardiovascular risk factors: an age-period cohort analysis of 698,954 health examinations in 181,350 Austrian men and women. J Intern Med 2007;261:566–576.
3. Stranges S, Dorn JM, Muti P, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004;39:754–763.
4. Nakanishi N, Yoshida H, Nakamura K, Suzuki K, Tatara K. Predictors for development of hyperuricemia: an 8-year longitudinal study in middle-aged Japanese men. Metabolism 2001;50:621–626.
5. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999;22:1971–1977.
6. Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clin Chem Lab Med 2010;48:147–157.
7. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132–140.
8. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170–180.
9. Kuzuya M, Ando F, Iguchi A, Shimokata H. Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol A Biol Sci Med Sci 2002;57:M660-M664.
10. Lee DH, Ha MH, Kam S, et al. A strong secular trend in serum gamma-glutamyltransferase from 1996 to 2003 among South Korean men. Am J Epidemiol 2006;163:57–65.
11. Daeppen JB, Smith TL, Schuckit MA. Influence of age and body mass index on gamma-glutamyltransferase activity: a 15-year follow-up evaluation in a community sample. Alcohol Clin Exp Res 1998;22:941–944.
12. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63:3136–3141.
13. Ong KL, Allison MA, Cheung BM, Wu BJ, Barter PJ, Rye KA. Trends in C-reactive protein levels in US adults from 1999 to 2010. Am J Epidemiol 2013;177:1430–1442.
14. Verschuren WM, Blokstra A, Picavet HS, Smit HA. Cohort profile: the Doetinchem Cohort Study. Int J Epidemiol 2008;37:1236–1241.
15. Thapa BR, Walia A. Liver function tests and their interpretation. Indian J Pediatr 2007;74:663–671.
16. Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 2003;107:370–371.
17. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20–29.
18. Dreon DM, Slavin JL, Phinney SD. Oral contraceptive use and increased plasma concentration of C-reactive protein. Life Sci 2003;73:1245–1252.
19. van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006;4:77–82.
20. Silvestri A, Gebara O, Vitale C, et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:3165–3169.
21. Rhone DP, White FM. Effects of storage in the cold on activity of gamma-glutamyltransferase in serum. Clin Chem 1976;22:103–104.
22. Wilson SS, Guillan RA, Hocker EV. Studies of the stability of 18 chemical constituents of human serum. Clin Chem 1972;18:1498–1503.
23. Jansen E, Beekhof P, Viezeliene D, Muzakova V, Skalicky J. Long-term stability of cancer biomarkers in human serum: biomarkers of oxidative stress and redox status, homocysteine, CRP and the enzymes ALT and GGT. Biomark Med 2015;9:425–432.
24. Ishikawa S, Kayaba K, Gotoh T, et al. Comparison of C-reactive protein levels between serum and plasma samples on long-term frozen storage after a 13.8 year interval: the JMS Cohort Study. J Epidemiol 2007;17:120–124.
25. Azar RR, Klayme S, Germanos M, et al. Effects of aspirin (325 mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhesion molecules in healthy volunteers. Am J Cardiol 2003;92:236–239.
26. Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036–2041.
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
28. Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT. Distribution and determinants of C-reactive protein in the older adult population: European Prospective Investigation into Cancer-Norfolk study. Eur J Clin Invest 2013;43:899–911.
29. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737–1742.
30. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499–516.
31. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679–689.
32. Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 1986;10:255–264.
33. Matsuura F, Yamashita S, Nakamura T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998;47:929–933.
34. Warren RS, Starnes HF Jr, Gabrilove JL, Oettgen HF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396–1400.
35. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111–2119.
36. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7:147–159.
37. Raho E, van Oostrom SH, Visser M, et al. Generation shifts in smoking over 20 years in two Dutch population-based cohorts aged 20-100 years. BMC Public Health 2015;15:1481.
38. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916–1922.
39. Poikolainen K, Vartiainen E. Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol 1997;146:1019–1024.
40. McEvoy JW, Nasir K, DeFilippis AP, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:1002–1010.